Analysts Have Conflicting Sentiments on These Healthcare Companies: Collegium Pharmaceutical (COLL) and Intellia Therapeutics (NTLA)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Collegium Pharmaceutical (COLL – Research Report) and Intellia Therapeutics (NTLA – Research Report).
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Collegium Pharmaceutical (COLL)
In a report released today, Serge Belanger from Needham maintained a Buy rating on Collegium Pharmaceutical, with a price target of $54.00. The company’s shares closed last Thursday at $43.97.
According to TipRanks.com, Belanger is a 5-star analyst with an average return of
Currently, the analyst consensus on Collegium Pharmaceutical is a Strong Buy with an average price target of $57.00.
See Insiders’ Hot Stocks on TipRanks >>
Intellia Therapeutics (NTLA)
William Blair analyst Myles Minter maintained a Hold rating on Intellia Therapeutics today. The company’s shares closed last Thursday at $13.97.
According to TipRanks.com, Minter is a 5-star analyst with an average return of
Intellia Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $16.38.
